Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Generate BiomedicinesGENB +4.48%6 Cash Ratio is 2.69 as of Dec. 2025, which is 26% below its 10-year median of 3.62. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review. Among 1,381 Biotechnology companies, Generate Biomedicines ranks worse than 52.5% on this metric.
Generate Biomedicines has a Cash Ratio of 2.69. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Generate Biomedicines's Cash Ratio or its related term are showing as below:
GENB'
s Cash Ratio Range Over the Past 10 Years
Min: 2.69 Med: 3.62 Max: 4.54
Current: 2.69
During the past 2 years, Generate Biomedicines's highest Cash Ratio was 4.54. The lowest was 2.69. And the median was 3.62.
GENB's Cash Ratio is ranked worse than 52.5% of 1381
companies
in the Biotechnology industry
Industry Median: 2.96
vs GENB: 2.69
Generate Biomedicines (NAS:GENB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generate Biomedicines Cash Ratio Chart
Generate Biomedicines Annual Data
Trend
Dec24
Dec25
Cash Ratio
4.54
2.69
Generate Biomedicines Semi-Annual Data
Dec24
Dec25
Cash Ratio
4.54
2.69
GENB vs ZYME, DMRA, SLBT: Cash Ratio Comparison
For the Biotechnology subindustry, Generate Biomedicines's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Generate Biomedicines Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Generate Biomedicines's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Generate Biomedicines's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generate Biomedicines (GENB) has a Cash Ratio of 2.69 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Generate Biomedicines and its competitors. This is 26% below median its historical median of 3.62. Over the past decade, Generate Biomedicines' Cash Ratio has ranged from 2.69 to 4.54. According to the industry distribution chart, Generate Biomedicines ranks #725 out of 1381 companies in the Biotechnology industry, placing it in the top 52.5%.
Is Generate Biomedicines' Cash Ratio too high?
Generate Biomedicines' current Cash Ratio of 2.69 is 26% below median its 10-year median of 3.62. Over the past 10 years, this metric has ranged from a low of 2.69 to a high of 4.54. The Biotechnology industry median Cash Ratio is 2.96. Generate Biomedicines' value of 2.69 is 9.1% below this industry median. Based on the distribution chart, Generate Biomedicines ranks #725 out of 1381 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Cash Ratio compare to ZYME and DMRA?
According to the Biotechnology industry distribution chart, Generate Biomedicines ranks #725 out of 1381 companies for Cash Ratio. This places Generate Biomedicines in the lower half of its industry. The industry median Cash Ratio is 2.96. Generate Biomedicines' value of 2.69 is 9.1% below this benchmark. Historically, Generate Biomedicines' own Cash Ratio has ranged from 2.69 to 4.54 over the past decade. While the company's 10-year median is 3.62 vs. the industry median of 2.96, Generate Biomedicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,381 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Generate Biomedicines's current Cash Ratio of 2.69 is 9.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Generate Biomedicines and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Generate Biomedicines's current Cash Ratio is 2.69, which is 26% below median its own 10-year median of 3.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Cash Ratio of 2.69. The current Cash Ratio is 2.69, which is 26% below median its 10-year median of 3.62 and 9.1% below the Biotechnology industry median of 2.96. Generate Biomedicines' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Cash Ratio is 2.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score
Get the complete analysis for GENB
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GENB has been successfully added to your 
